ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Michel BAIJOT is the current CEO.

davidplas 44874 300Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection.

This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness.

ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ - in ongoing phase III - and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market.

The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and its facilities in Liège, Belgium.

History


 

Key milestones 


2010   BTT-gpASIT004 Phase I study: demonstration of safety and immunogenicity of subcutaneous administration of gp-ASIT+TM, a product candidate for the treatment of grass pollen rhinitis
     
2012   BTT-gpASIT006 Phase IIa study: demonstration of a one year lasting effect of gp-ASIT+TM, a product candidate for the treatment of grass pollen rhinitis
     
2014  

BTT-gpASIT007 Phase IIa study: proof of concept reached by the demonstration of the clinical effect of gp-ASIT+TM on an allergen provocation test
BTT-gpASIT008 Phase IIb study: selection of the optimal dose/regimen of gp-ASIT+TM to be tested in the phase III clinical study
BTT- hdm-ASIT+TM: initiation of the regulatory preclinical development of a product candidate for the treatment of house dust mite asthma

     
2015  

ASIT biotech rises the funds necessary to run the first phase III clinical study with gp-ASIT+TM
BTT-gpASIT009 Phase III study: launch of the clinical study in 6 European countries
BTT- hdm-ASIT+TM: completion of the regulatory preclinical development

     
2016  

 Asit biotech successfully completes its initial public offering on Euronext Brussels and Euronext Paris and raises €23.5M

     
2017  

 The first Phase III clinical study with gp-ASIT+™ in grass pollen rhinitis

International collaboration with Imperial College London and King’s College Hospital in a rational drug design program for the screening of other ASIT+™ products

     
2018  

Selection of pnt-ASIT+™, product candidate in the domain of food allergies, specifically targeting peanut allergy

Selection of a new hdm-ASIT+™, product candidate in house dust mite allergy, with an improved immunological profile

Launch of a confirmatory phase III study for gp-ASIT+™ in grass pollen rhinitis